Anderson WC, et al. - Researchers assessed the cost-efficacy and comparative effectiveness of FDA-approved biologics for the treatment of asthma by analyzing relevant studies and documents published 2016-2019. Upon analysis, they found current pricing for all biologics exceeded measures of cost-effectiveness. A minimum reduction of ~60% in prices would be required in order to meet available measures indicating cost-effectiveness. Identification of predictors of response among those receiving oral corticosteroid therapy and evaluation of the influence of treatment for decisions that relate to continuation are the key aspects that should be emphasized to maximize cost-effectiveness of the biologics, according to the investigators. Responsible application of biologic therapy may be ensured with multidisciplinary stakeholder efforts.